Cassava Sciences Stock (NASDAQ:SAVA)
Previous Close
$2.82
52W Range
$2.23 - $42.20
50D Avg
$2.55
200D Avg
$16.38
Market Cap
$135.75M
Avg Vol (3M)
$2.30M
Beta
-1.24
Div Yield
-
SAVA Company Profile
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
SAVA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| TGTX | TG Therapeutics, Inc. |
| AVXL | Anavex Life Sciences Corp. |
| INMB | INmune Bio, Inc. |
| EXEL | Exelixis, Inc. |
| VKTX | Viking Therapeutics, Inc. |
| MDGL | Madrigal Pharmaceuticals, Inc. |
| KRYS | Krystal Biotech, Inc. |
| AXSM | Axsome Therapeutics, Inc. |
| BTAI | BioXcel Therapeutics, Inc. |
| MCRB | Seres Therapeutics, Inc. |
| VIR | Vir Biotechnology, Inc. |
| ANVS | Annovis Bio, Inc. |